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Abstract Alzheimer’s disease (AD) is a genetically com-
plex disorder, and several genes related to cholesterol
metabolism have been reported to contribute to AD risk.
To identify further AD susceptibility genes, we have
screened genes that map to chromosomal regions with high
logarithm of the odds scores for AD in full genome scans
and are related to cholesterol metabolism. In a European
screening sample of 115 sporadic AD patients and 191
healthy control subjects, we analyzed single nucleotide
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polymorphisms in 28 cholesterol-related genes for associ-
ation with AD. The genes HMGCS2, FDPS, RAFTLIN,
ACAD8, NPC2, and ABCG1 were associated with AD at a
significance level of P≤0.05 in this sample. Replication
trials in five independent European samples detected
associations of variants within HMGCS2, FDPS, NPC2,
or ABCG1 with AD in some samples (P=0.05 to P=0.005).
We did not identify a marker that was significantly
associated with AD in the pooled sample (n=2864).
Stratification of this sample revealed an APOE-dependent
association of HMGCS2 with AD (P=0.004). We conclude
that genetic variants investigated in this study may be
associated with a moderate modification of the risk for AD
in some samples.
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Introduction
Cholesterol influences processes that are central to the
pathogenesis of Alzheimer’s disease (AD) [1]. In support of
experimental and epidemiological evidence, population
genetics suggest a role of cholesterol in the pathophysiol-
ogy of AD [2]. The ɛ4 allele of APOE, the gene encoding
the major apolipoprotein of the central nervous system is
the only well-established genetic risk factor for sporadic
AD. However, several other genes related to cholesterol
metabolism have been associated with AD risk, albeit with
conflicting findings in subsequent replication trials (The
AlzGene Database, http://www.alzgene.org). With respect
to the complex nature of the genetics of both cholesterol
metabolism and AD, we have recently conducted a set
association study in which we have shown an additive
effect of polymorphisms in cholesterol-related genes for
which association with AD risk had been published in
previous single gene studies [3]. Against this background,
we investigated further genes from the same functional
context for association with the risk for AD in a targeted
screen of cholesterol-related genes. Full genome scans have
identified chromosomal regions with high logarithm of the
odds (LOD) scores for AD which supposedly harbor AD
susceptibility genes [4, 5]. Because positional candidate
gene selection might reduce the prior probability of false
positive associations, we confined our screen to AD-linked
chromosomal regions [6].
In this paper, we report that of 28 investigated genes,
HMGCS2, FDPS, RAFTLIN, ACAD8, NPC2, and ABCG1
were associated with the risk for sporadic AD in a small
screening sample. However, none of the observed associ-
ations could be consistently replicated.
Materials and methods
Patients and control subjects
Case control samples for sporadic AD from six independent
clinical centers in Switzerland, Germany, Poland, Belgium,
Sweden, and Greece were included in genetic association
studies. Clinical diagnosis of probable AD was made
according to the NINCDS-ADRDA criteria [7]. Dementia
and memory deficits in geographically matched control
subjects were excluded by neuropsychological testing,
consisting of the “Consortium to Establish a Registry for
Alzheimer’s Disease” (CERAD) neuropsychological test
battery and the “mini mental status examination” (MMSE).
Cases and controls from the German series were histopath-
ologically confirmed. The local Ethics Committees ap-
proved of the study, and informed consent was obtained
before the investigation. Table 1 summarizes the sample
characteristics. Screening was done in a random subsample
of the Swiss series comprising 115 AD cases and 191
healthy control subjects (HCS).
Chromosomal regions
To define chromosomal regions of interest, we used the
high-resolution family-based full genome scans by Myers et
al. [4] and Blacker et al. [5] as a basis. To transpose the
positional information from the Marshfield linkage map to the
NCBI sequence map, we used the mapping information of
the ‘UniSTS integrating markers and maps’ data base (http://
www.ncbi.nlm.nih.gov/). We took the sequence map position
of the microsatellite marker with the highest signal for a
linkage peak as a reference point for our interval of interest.
The interval comprised the Zmax-1 support interval of the
peak marker, all sections of a peak with LOD scores >1, and
at least 5 cm upstream and downstream the peak marker
assuming a linear correlation of distance between the linkage
and the sequence map. For chromosome 10, we investigated
an arbitrary interval comprising additional information from
several fine mapping studies [8–11]. Table 2 summarizes the
investigated chromosomal regions.
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Gene selection
Relation of a gene to cholesterol metabolism was assumed
based on the combined information from keyword-based
searches of the following databases: NCBI EntrezGene
(http://www.ncbi.nlm.nih.gov/), GeneCards (http://bioinfo.
weizmann.ac.il/cards/index.shtml) genmap pathways
(http://www.genmapp.org), Gene ontology consortium
(http://www2.ebi.ac.uk/), The Kegg website: (http://www.
genome.ad.jp/kegg/kegg.html). Genes that had an estab-
lished or probable role in cholesterol metabolism where
checked for localization in the chromosomal regions
defined above. Conversely, genes in these chromosomal
regions were checked for a role in cholesterol metabolism
based on the NCBI EntrezGene gene description. Although
thorough, this selection process does not warrant complete-
ness. Forty-five (45) genes fulfilled both the functional and
the positional inclusion criteria (Table 2). Fourteen (14) of
these genes had been investigated in previous studies with
positive or negative results [12–25] (including unpublished
observations). The remaining 28 genes were included in the
present study (Table 3).
Table 2 Compilation of the microsatellite markers and their position in base pairs (bp) on the NCBI sequence map that define high LOD score
peaks for Alzheimer’s disease (AD) in two full genome scans (Myers et al., Blacker et al.) [4, 5]
Chromosome Marker Reference Sequence map
position (bp)
Interval (bp) Cholesterol-related genes in
interval
1 D1S1675 Myers et al. 114541676–114541910 100000000–180000000 HMGCS2, PRKAB2, PMVK, APOA1BP,
FDPS, APOA2, RXRG, SOAT1aD1S1677 Blacker et al. 161826325–161826527
3 D3S2387 Blacker et al. 1011272–1011460 0–20000000 PPARGa, RAFTLIN
4 D4S1629 Blacker et al. 158556260–158556399 150000000–170000000
5 D5S1470 Myers et al. 32528047–32528242 22500000–47500000 PRKAA1, HMGCS1
6 D6S1018 Myers et al. 47420389–47420540 29000000–55000000 FLOT1, APOMa, RXRB, PPARDa,
APOBEC2, CYP39A1D6S1017 Blacker et al. 41785174–41785332
D6S1027 Blacker et al. 168951275–168951405 154000000–ter. ACAT2, LPA
9 D9S741 Myers et al. 24524138–24524340 15000000–45000000
D9S283 Blacker et al. 91604245–91604380 68000000–110000000 ABCA1a
D9S176 Myers et al. 101098125–101098298
10 D10S1237 var. 116109983–116110380 46800000–126000000 ACF, FLJ22476a, AP3M1, CH25Ha, LIPAa
11 D11S968 Blacker et al. 133323661–133323811 100000000–ter. APOA4a, APOC3a, APOA1a, ABCG4,
ZNF202, ACAD8
12 LOX1 Myers et al. 10202167–10216004 5000000–15000000 APOBEC1, OLR1a, LRP6a
14 D14S587 Blacker et al. 53436576–53436854 44000000–82000000 NPC2
15 D15S642 Blacker et al. 100152332–100152540 90000000–ter.
19 D19S178 Blacker et al. 49097441–49097642 29000000–71000000 LRP3, LIPE, APOEa, APOC1a,
APOC2a, NR1H2aD19S412 Myers et al. 51702822–51702951
21 D21S1909 Myers et al. 31455187–31455426 11000000–48000000 ABCG1, LSS
D21S1440 Blacker et al. 38063497–38063658
X DXS8015 Myers et al. 39669120–39669305 25000000–54000000 EBP
Intervals representing peak configurations were searched for genes related to cholesterol metabolism. For chromosome 10, information from
various studies (var.) [8–11] was included. Forty-five cholesterol-related genes were identified in these intervals. Genes in italics were associated
with AD risk in the screening sample (P≤0.05 in Pearson’s χ2 tests of individual SNPs or haplotypes).
a Genes with preexisting association data were not investigated in the present study.
Table 1 Characteristics of the investigated samples
Group size (HCS/AD) Age (HCS/AD) % Females (HCS/AD) % APOE ɛ4 + (HCS/AD)
Switzerland (n=352) 207/145 66.81±9.4/68.1±9.19 51.2/50.3 32.2/59.3
Germany (n=117) 77/40 71.52±8.36/80.75±6.82 40.3/65.0 25.8/53.3
Poland (n=460) 240/220 69.68±7.39/77.19±4.64 71.7/69.1 23.8/58.6
Belgium (n=1200) 464/736 58.55±15.99/75.28±8.52 54.1/66.3 30.3/54.1
Sweden (n=361) 169/192 72.79±5.81/77.09±7.41 62.1/62.3 29.9/60.2
Greece (n=374) 98/276 67.54±8.06/69.23±8.33 57.1/62.0 19.8/46.8
“Age” is age at examination for HCS, age at onset for patients (AD), and age of death in the histopathologically confirmed German sample.
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SNP selection
Information on single nucleotide polymorphisms (SNPs)
was derived from the NCBI dbSNP database. Eighty-four
(84) SNPs corresponding to a mean resolution of ∼10 kb,
on average, ∼40% of the genetic variation of the investi-
gated loci that would be covered by a set of tagging SNPs
with a genotype correlation of <90% and a minor allele
frequency of >5%, and on average, three SNPs per gene,
were selected by the following criteria. (1) High validation
status: Ideally, SNPs reported by several independent
sources were selected. (2) Appropriate position: Ideally,
the SNPs selected for a gene covered the locus from
upstream the 5′ end to downstream the 3′ end (the average
position of the most 5′ marker was 2,663 bp upstream of
the start codon, and the average position of the most 3′
marker was 230 bp downstream of the stop codon). (3)
Informative allele frequencies: Ideally, SNPs with a
reported minor allele frequency of >10% were selected.
Information on linkage disequilibrium obtained from the
Celera data base (SNPbrowser Version 2.0, Applera) was
taken into consideration in the decision on SNP number and
position. SNPs for which no reliable assay could be
established, SNPs that did not show informative allelic
distribution in our screening sample, and SNPs with strong
distortion of Hardy–Weinberg equilibrium (P<0.01) in the
control group of the screening sample were discarded and
replaced by new markers. Further markers were also
introduced where the most 5′ or 3′ SNPs yielded positive
signals to facilitate delimitation from neighboring loci.
Table 3 compiles the SNPs investigated as markers for the
respective genes (more detailed information on the selected
SNPs is provided in “electronic supplementary material”
Table 5).
Genotyping
Genomic DNA was isolated from ethylenediaminetetra-
acetic acid blood using QIAamp DNA blood kits (Qiagen).
Genotyping was done using the KASPar method (KBio-
sciences, http://www.kbioscience.co.uk). In the Belgian
series, genotyping was done using 2 SEQUENOM mass
array spectrometry multiplex assays, except for rs3827225
and rs692382 (direct sequencing) and rs651347 and
rs1441008 (Pyrosequencing). On request, we will provide
details on the individual assays including primers.
Statistics
To calculate Hardy–Weinberg equilibrium, to analyze linkage,
and to reconstruct haplotypes based on pair-wise linkage
disequilibrium (LD) between contributing SNPs, we used
PowerMarker Version 3.22 (http://www.powermarker.net).
We considered only those haplotypes for which the gametic
phase could be predicted with a probability of ≥95% in
every individual without missing data on contributing SNPs.
To assess association with AD, frequencies of genetic
markers were compared between AD and HCS groups in
Pearson’s χ2 tests (SPSS 12.0 for Windows). Statistical
Table 3 Investigated genes and SNPs
Gene SNPs 5′–3′
HMGCS2 rs1441008, rs651347, rs668156, rs532208, rs608358
(HC-T-G-G, OR=1.77, 95% CI=1.05–2.97, χ
2=4.71,
P=0.03)
PRKAB2 rs1348316, rs2304893
PMVK rs877343, rs1007170
APOA1BP rs942960
FDPS rs4971072, rs2297480, rs11264359, rs11264361
(HA-G-T, χ
2=4.06 P=0.04)
APOA2 rs5082
RXRG rs100537, rs285480, rs283690
RAFTLIN rs6442608, rs6768991, rs1346604, rs6442605,
rs1517516, rs2077624, rs1965432, rs6900 (rs6768991C,
OR=1.45, 95% CI=1.04–2.01,
χ2=4.89, P=0.03)
PRKAA1 rs466108, rs3805492, rs29742
HMGCS1 rs1548097, rs6814
FLOT1 rs15297, rs8233
RXRB rs2076310, rs2072915
APOBEC2 rs2073016, rs11280
CYP39A1 rs3757241, rs3799866, rs3799877, rs699938
ACAT2 rs2277073, rs4832
LPA rs1406888, rs1569933, rs3798221, rs3124785
ACF rs3808919, rs4935194, rs10821846
AP3M1 rs3812639, rs6688, rs3809046,
ABCG4 rs3809046, rs668033, rs3802885
ZNF202 rs675172
ACAD8 rs570113, rs561945, rs514417 (HC-G-G, OR=0.45, 95%
CI=0.22–0.93, χ2=4.88, P=0.03)
APOBEC1 rs7316755, rs2302515
NPC2 rs1468503, rs917394, rs1860108, rs1029699 (HG-C-T-T,
OR=2.12, 95% CI=1.17–3.84, χ2=6.23, P=0.01)
LRP3 rs3760890, rs875550
LIPE rs851301, rs1206034
ABCG1 rs9976212, rs1378577, rs692383, rs3827225, rs225448,
rs225378, rs425215, rs1044317 (rs692383G, OR=1.82,
95% CI=1.28–2.58, χ2=11.48, P=0.0007)
LSS rs999689, rs2839158, rs2075906, rs2254524, rs2968
EBP rs11091236
Italicized letters indicate allelic or genotypic association of SNPs or
their haplotypes, with AD assuming statistical significance at
nominal P values of ≤0.05 in Pearson’s χ2 tests for allelic, genotypic,
or haplotype association. These genes and SNPs were tested in an
enlarged Swiss sample and in independent replication samples.
Statistics are given only for the strongest effect of the respective
gene. Odds ratios (OR) and corresponding confidence intervals (CI)
refer to presence of the indicated allele or genotype of the respective
SNP and to presence of the haplotype (H). Haplotype-defining alleles
of the contributing SNPs are indicated from 5′ to 3′.
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significance was assumed for allelic, genotypic, or haplotype-
specific associations with nominal P values of ≤0.05.
Corrections for multiple testing were not applied because
with 29 independent genes and 88 markers, this very
stringent procedure would have precluded the detection of
moderate effects. Instead, positive findings in the screening
sample were validated by sample enlargement and by
replication trials in five independent additional samples. In
the validation stage, i.e., in the enlarged Swiss sample and in
the other five samples as well as in combined analyses, we
applied unconditional forward and backward logistic regres-
sions to adjust for age, sex, center (combined analyses)
presence or absence of at least one APOE ɛ4 allele, and all
SNPs and haplotypes of the respective gene (SPSS 12.0 for
Windows). Statistical significance was assumed for associ-
ations with adjusted P values of ≤0.05. For power analyses
we used Power Calculator (http://calculators.stat.ucla.edu/
powercalc/).
Results
The screening of 28 cholesterol-related genes with 84 SNPs
in a sample of 115 AD cases and 191 HCS identified six
candidate genes supported by nominal P values of ≤0.05 in
Pearson’s χ2 tests of allelic, genotypic, or haplotype
association (Table 3; on request, genotype details of all
markers tested in the screening sample will be provided).
Five of six genes showed P values of ≥0.01 (HMGCS2,
FDPS, RAFTLIN, ACAD8, NPC2). The only gene signif-
icant at a higher level was ABCG1 (rs692383, P=0.0007,
allelic association).
To validate these observations, we investigated variants
within HMGCS2, FDPS, RAFTLIN, ACAD8, NPC2, and
ABCG1 in an enlarged Swiss sample and in five indepen-
dent replication samples of European origin. We genotyped
19 SNPs that either alone or as haplotypes were associated
with AD risk in the screening sample.
Sample enlargement removed the initial significance of
HMGCS2, RAFTLIN, and NPC2 in the Swiss series.
Association of HMGCS2, FDPS, NPC2, and ABCG1
variants with AD was observed in at least one of the five
replication samples on a gene basis at a significance level of
P≤0.05. However, effects were contributed by different
markers of the same gene (e.g., FDPS: HA-G-A in Switzer-
land; HA-T-A in Sweden) or had inverse directionality (e.g.,
ABCG1 HC-G: OR 1.65, 95% CI 1.06–2.59 in Switzerland;
OR=0.67, 95% CI=0.46–0.98 in Poland) in different
samples (Table 4, “electronic supplementary material”
Tables 1 and 2). Exclusion of individuals <65 years of age
did not significantly change the results (data not shown).
Previous to sample pooling for combined analyses, we
compared sex distribution, age, and APOE ɛ4 prevalence
between the control groups of the six samples. Sex
distribution and age showed strong center dependence
(P<0.000001). Notably, allelic or genotypic frequencies of
some investigated SNPs (HMGCS2: rs651347, rs668156;
ACAD8: rs570113, rs561945, rs514417; ABCG1:
rs1378577) were also distributed differentially across
control groups at significance levels of P=0.05 to P=
0.002. This indicated that the comparability of the
investigated samples may be limited and that sample
admixture may produce false positive or false negative
findings in combined analyses. Therefore, we excluded
center-dependent genetic markers and haplotypes contain-
ing these markers from analyses in the pooled sample (n=
2864). The analysis of all remaining SNPs and haplotypes
did not produce consistent association of a locus with AD.
Only markers for NPC2 (rs1860108, rs1029699, HG-C-C-C)
were positive at a low significance level (P>0.01).
However, this effect was completely dependent on the
observed association of these markers with AD in the small
German sample, and logistic regression adjusting for age,
sex, center, and APOE removed its significance. Exclusion
of the younger participants (<65 years of age) and
stratification for sex did not affect the result of the
combined analysis. However, stratification for the presence
or absence of at least one APOE ɛ4 allele produced an
effect of HMGCS2, as rs532208 was associated with AD in
the APOE-ɛ4-positive stratum with the G allele as a risk
factor and the C allele being protective (n=1182, OR=1.28,
95% CI 1.07–1.53, χ2=7.03, P=0.008, P=0.004 after
correction for age, sex, center, and all other HMGCS2
markers tested in the combined sample, Tables 5 and 6).
Rs1441008 was also associated with AD in an APOE-
dependent manner (Tables 5 and 6). Reassessment of the
six individual samples revealed association of at least one
HMGCS2 marker with AD in the APOE-ɛ4-positive or the
APOE-ɛ4-negative stratum for every sample at significance
levels of P=0.03–0.002 (Table 7).
Discussion
In the present study, we have conducted a case control
association study with those genes that are functionally
related to cholesterol metabolism and are localized in
chromosomal regions with high LOD scores for AD and
are, therefore, both functional and positional candidate
susceptibility genes for AD. During screening in a limited
cohort of AD patients and healthy control subjects, most of
the genes investigated with, on average, three SNPs were
negative and were excluded from further analyses. This
does not definitely exclude that these genes may be
associated with AD because the statistical power of the
screening process was low (the relative risk detectable with
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80% power at a significance level of P=0.05 was 0.224 or
2.525 for a marker with a minor allele frequency of 0.1), and
the markers used for the investigated genes did not capture
the whole genetic variability of the respective loci in terms of
linkage and allele frequencies. Notably, recent studies have
shown that even a dense set of tagging SNPs may be
insufficient to definitely exclude association [26, 27]. Six
genes, HMGCS2, FDPS, RAFTLIN, ACAD8, NPC2, and
Table 5 Genotypic distribution of the HMGCS2 SNP rs532208 in the pooled sample stratified by presence or absence of at least one APOE ɛ4
allele
rs532208 GG GT TT
HCS APOE ɛ4 positive 80 (23.5%) 163 (47.8%) 96 (28.7%)
AD APOE ɛ4 positive 238 (28.3%) 423 (50.3%) 180 (21.4%)
OR=1.28, 95% CI 1.07–1.53, χ2=7.03, P=0.008, (P=0.004)
HCS APOE ɛ4 negative 237 (27.4%) 425 (49.1%) 203 (23.5%)
AD APOE ɛ4 negative 178 (25.7%) 352 (50.8%) 163 (23.5%)
OR=0.97, 95% CI 0.84–1.11, χ2=0.24, P=0.62, (P=0.33)
Statistics refer to the comparison of the numbers of G vs T alleles (rs532208) between the HCS and AD group. The italicized P value refers to the
unadjusted Pearson’s χ2 test. The P value in parentheses was obtained by logistic regression adjusting for sex, age, center, and all HMGCS2
markers tested in the pooled sample.
Table 4 Markers associated with AD in the individual samples
Switzerland
(n=352)
Germany
(n=117)
Poland
(n=460)
Belgium
(n=1,200)
Sweden
(n=361)
Greece
(n=374)
HMGCS2 HT-G-G-G, OR=1.39,
95% CI=1.01–
1.91, χ2=4.14, P=
0.04 (P=0.02)
HT-G-G-G, OR=2.15,
95% CI=1.11–
4.18, χ2=5.27, P=
0.02 (P=0.02)
HT-G-A-T, OR=
0.58, 95%
CI=0.35–0.98,
χ2=4.40, P=
0.04 (P=0.03)
FDPS HA-G-A, χ
2=5.75,
P=0.02 (P=0.02)
HA-T-A, OR=4.24,
95% CI=1.37–
13.16, χ2=7.28,
P=0.007 (P=
0.007) rs2297480,
rs11264359,
rs11264361
ACAD8 HA-T-A, OR=0.48,
95% CI=0.25–0.93,
χ2=4.93, P=0.03
(P=0.02)
NPC2 HG-C-C-C, OR=3.16,
95% CI=1.39–7.20,
χ2=7.76, P=0.005
(P=0.05) rs1860108,
rs1029699
ABCG1 Rs692383G, OR=1.66,
95% CI=1.20–2.30,
χ2=9.26, P=0.002 (P=
0.003) rs1378577,
rs3827225, HA-A
a, HC-G
a
HC-G
a, OR=0.67,
95% CI=0.46–
0.98, χ2=4.37,
P=0.04
(P=0.04)
P values in italics refer to unadjusted Pearson’s χ2 tests. P values in parentheses were obtained by logistic regressions adjusting for sex, age,
APOE, and all markers of the respective gene. Odds ratios (OR) and corresponding confidence intervals (CI) refer to presence of the indicated
allele or genotype of the respective SNP and to presence of the haplotype (H). Haplotype-defining alleles of the contributing SNPs are indicated
from 5′ to 3′ according to Table 3.
a Haplotypes of ABCG1 comprise only rs1378577 and rs692383.
Statistical details are given for the strongest effect. The other listed markers were positive on a lower significance level. Genotypic and haplotypic
distributions are provided as “electronic supplementary material” (Tables 1 and 2)
184 Neurogenetics (2007) 8:179–188
ABCG1, were positive, assuming statistical significance at
nominal P values of ≤0.05. Only ABCG1 was associated
with AD at a substantially higher significance level.
To test if these observations were of any relevance beyond
the investigated screening sample, we genotyped positive
markers in an enlarged sample and in five independent
Caucasian samples from different European countries. None
of the markers showed a consistent effect across the
investigated samples. Only stratification for the presence or
absence of at least one APOE ɛ4 allele revealed a weak
effect of HMGCS2. These findings argue against major
effects of the investigated genetic variants on AD risk.
Significant differences between the control groups of the
individual samples in age, sex distribution, and, notably,
allelic and genotypic frequencies of some of the SNPs
investigated in the present study limited the significance of
a pooled analysis. Separate analyses of the samples
confirmed association of HMGCS2, FDPS, NPC2, and
ABCG1 with AD in at least one sample. However, across
the samples, effects were carried by different SNPs or
haplotypes, or the same markers showed inverse odds
ratios. Our findings reflect the common problem of
replication failure and inconsistency in case control
association studies. It may be explained by false positivity
of the original observation, i.e., type I errors. Population-
specific effects of the investigated genes, owing to genetic
background and environmental factors, may also explain
inconsistencies between trials in independent samples.
Differences in linkage and allele frequencies between
different samples may lead to population-specific validity
of genetic markers, which can explain inconsistency and
inverse directionality of associations when the investigated
genetic markers are not the functional variables underlying
the observed effects. Moreover, differences in the distribu-
Table 7 All HMGCS2 markers that showed APOE-dependent associated with AD in the individual samples
APOE ɛ4 positive APOE ɛ4 negative
Switzerland HT-T-G-G, χ
2=7.66, P=0.006 (P=0.006) HC-T-G-G, OR=2.04, 95% CI 1.0–4.14, χ
2=3.93,
P=0.05 (P=0.04)
Germany rs668156, χ2=5.87, P=0.02 (P=0.02)
rs532208, ORGT=8.12, 95% CI 1.95–33.73, χ
2=9.85,
P=0.002 (P=0.02)
HT-G-G-T, χ
2=6.87, P=0.009 (P=0.009)
HT-G-A-T, χ
2=5.49, P=0.02 (P=0.02)
Poland rs651347, ORGT=1.73, 95% CI 1.04–2.89, χ
2=4.5,
P=0.03 (P=0.05)
Belgium rs651347, ORT=1.48, 95% CI 1.08–2.03, χ
2=5.93, P=0.02 (P=0.01)
rs532208, ORG=1.45, 95% CI 1.1–1.91, χ
2=6.89, P=0.009 (P=0.002)
HT-G-G-T, OR=0.66, 95% CI 0.43–1.01, χ
2=3.7, P=0.05 (P=0.05)
Sweden HT-G-G-G, OR=2.55, 95% CI 1.08–6.0, χ
2=4.76,
P=0.03 (P=0.02)
Greece HT-G-G-T, OR=2.11, 95% CI 1.15–3.86, χ
2=5.91,
P=0.02 (P=0.009)
Italicized P values refer to unadjusted Pearson’s χ2 tests. P values in parentheses were obtained by logistic regressions adjusting for sex, age, and
all HMGCS2 markers. Odds ratios (OR) and corresponding confidence intervals (CI) refer to presence of the indicated allele or genotype of the
respective SNP and to presence of the haplotype (H). Haplotype-defining alleles of the contributing SNPs are indicated from 5′ to 3′ according to
Table 3. Genotypic and haplotypic distributions are provided as “electronic supplementary material” (Tables 3 and 4)
Table 6 Genotypic distribution of the HMGCS2 SNP rs1441008 in the pooled sample stratified by presence or absence of at least one APOE ɛ4
allele
rs1441008 CC CT TT
HCS APOE ɛ4 positive 29 (8.7%) 139 (41.5%) 167 (49.8%)
AD APOE ɛ4 positive 114 (13.5%) 362 (42.8%) 369 (43.7%)
OR=1.23, 95% CI 1.06–1.56, χ2=6.55, P=0.01, (P=0.02)
HCS APOE ɛ4 negative 128 (14.9%) 370 (43.0%) 362 (42.1%)
AD APOE ɛ4 negative 74 (10.8%) 321 (47.0%) 288 (42.2%)
OR=0.91, 95% CI 0.97–1.06, χ2=1.41, P=0.23, (P=0.26)
Statistics refer to the comparison of the numbers of C vs T alleles (rs1441008) between the HCS and AD group. The italicized P value refers to the
unadjusted Pearson’s χ2 test. The P value in parentheses was obtained by logistic regression adjusting for sex, age, center, and all HMGCS2
markers tested in the pooled sample.
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tion of factors like sex and age may affect the result of
replication trials even if the investigated populations are
genetically similar and share a similar environment. These
explanations may also apply for the present study.
Although only at low significance levels, we found
limited confirming evidence for association of HMGCS2,
FDPS, NPC2, and ABCG1 with AD. Therefore, these genes
may be discussed separately:
HMGCS2 (GeneID: 3158, NCBI Entrez Gene database,
http://www.ncbi.nlm.nih.gov/) encodes 3-hydroxy-3-meth-
ylglutaryl-Coenzyme A synthase 2. HMGCS2 is a homo-
logue of HMGCS1, a key enzyme in sterol biosynthesis and
is localized in the mitochondrion. It is the first and
regulating enzyme of the ketogenic pathway. Association
of this gene with AD in APOE ɛ4 allele carriers from the
pooled sample is in line with the APOE dependence of the
linkage peak on chromosome 1 in the full genome scan by
Myers et al. [4]. Separate analyses of the six samples
consistently showed APOE-dependent association of
HMGCS2 markers with AD. However, across samples,
these associations were observed for different markers,
showed different strength and directionality, and occurred
both in APOE-ɛ4-positive and in APOE-ɛ4-negative strata.
The interpretability of these observations is limited by the
small number of individuals in most of the sample strata.
Pure stratification artifacts seem unlikely because APOE-
dependent association of at least one HMGCS2 marker with
AD was observed in every sample. We assume that there
may be complex epistatic interactions between APOE and
genetic variables in LD with the investigated HMGCS2
markers that may directly or indirectly lead to the observed
effects. Other loci (PHGDH, REG4) are mapped in close
vicinity to HMGCS2. Therefore, definite attribution of the
signal to HMGCS2 would require fine mapping of the
region and possibly functional data in support of a role of
HMGCS2 in AD.
FDPS (GeneID: 2224, NCBI Entrez Gene database,
http://www.ncbi.nlm.nih.gov/) encodes farnesyl diphos-
phate synthase. FDPS is a key enzyme in the isoprene
biosynthetic pathway, which provides the cell with choles-
terol. Like for HMGCS2, definite attribution of the signal to
the gene is not possible with the present set of markers
(neighboring loci: PKLR, RUSC1).
NPC2 (GeneID: 10577, NCBI Entrez Gene database,
http://www.ncbi.nlm.nih.gov/) encodes Niemann–Pick dis-
ease type C2. NPC2 may be involved in regulating the
transport of cholesterol through the late endosomal/lysosom-
al system. Mutations in this gene have been associated with
Niemann–Pick disease type C2 and frontal lobe atrophy.
Also, here, delimitation of the signal from neighboring loci
(HBLD1, LTBP2) would require further analyses.
ABCG1 (GeneID: 9619, NCBI Entrez Gene database,
http://www.ncbi.nlm.nih.gov/) encodes ATP-binding cas-
sette transporter G1. ABCG1 is a half-size transporter that,
as a dimer, mediates cholesterol efflux via HDL particles.
Association of the related genes ABCA1 [16, 28, 29] and
ABCA2 [26, 30] with AD may be indirect support for a
similar effect of ABCG1. Association of paralogous genes
with AD has also been described for members of the GAPD
gene family [31]. The gene encoding the ABCG1 dimer-
ization partner ABCG4 was also investigated in the present
study, but was not associated with AD. We were able to
delineate the ABCG1 signal in the 5′ region of the gene.
Therefore, it seems unlikely that it stems from LD with a
different locus.
In previous studies, we and others have investigated
several genes related to the metabolism of cholesterol for
association with AD. Most of these studies were done with
very few markers of the respective genes, and independent
replication studies produced inconsistent results (The
AlzGene Database, http://www.alzgene.org). In a more
systematic approach, we have now investigated variants of
hitherto uninvestigated cholesterol-related genes that are
located in AD-linked chromosomal regions. The results of
this study reflect the outcome of previous association
studies that replication trials in independent populations
yield only inconsistent confirmative evidence for initially
observed associations. Of the cholesterol-related genes for
which we have described, association with AD CYP46A
[32] and ABCA1 [16] may be quoted as examples of loci
with several positive replication studies that are negative in
meta-analyses because of reciprocal effects between indi-
vidual populations (The AlzGene Database, http://www.
alzgene.org). On the other hand, individual replication
studies on an association of SOAT1 [12] with AD were
negative, but meta-analyses support a role of this gene in
AD (The AlzGene Database, http://www.alzgene.org).
The genetic variants investigated in the present study are
not associated with a strong and general modification of the
risk for AD. However, inconsistent findings for HMGCS2,
FDPS, NPC2, and ABCG1 may provide some support for a
role of further cholesterol-related genes in AD and may
warrant fine mapping studies of these loci. We assume that
identification of the functional variants that underlie
associations observed for the genetic markers investigated
in the present and in previous studies may help to overcome
the prevalent problem of inconsistent replications. Once
identified, these variants may form a cluster that, together
with the APOE ɛ2/3/4 haplotype, may genetically link
cholesterol metabolism and AD. Thus, the present study
may contribute to the uncovering of the complex genetic
underpinnings of this disease.
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